Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen Inc. (INGN) is a pioneering medical technology company committed to enhancing the quality of life for supplemental oxygen users. Founded in 2001, Inogen emerged from a personal story of necessity and innovation. The company's mission began when Mae, the grandmother of one of the founders, was prescribed oxygen therapy, highlighting the need for more user-friendly and portable oxygen solutions. You can learn more about Mae's story here.
Inogen aims to revolutionize oxygen therapy technology, striving to keep pace with the active lifestyles of patients who rely on oxygen to lead fulfilling lives. The company estimates that over 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy.
The company's flagship product, the Inogen One system, is a compact, lightweight, and travel-approved portable oxygen concentrator designed to liberate patients from the constraints of heavy tanks, frequent refills, and stationary systems. This innovation provides patients with the freedom and independence to live their lives by moments, not by the minutes left in an oxygen tank.
Inogen's products and services are sold through various channels, including home medical equipment providers, distributors, large gas companies, and home oxygen providers. The company also rents its products directly to patients, generating the majority of its revenue within the United States.
Inogen's commitment to continuous improvement is evident in its ongoing projects and recent achievements. The company constantly works toward refining its product offerings and expanding its reach to benefit more patients globally.
Inogen, Inc. (NASDAQ: INGN) reported a strong Q3 2021 performance with total revenue reaching $93.1 million, a 25.3% increase year-over-year. The domestic direct-to-consumer segment generated $36.3 million, up 24.6%, while rental revenue surged 61.3% to $12.1 million. Despite supply chain challenges, operating income was $6.4 million, and net income stood at $12.2 million, with an EPS of $0.53. However, full-year 2021 guidance remains uncertain due to ongoing semiconductor shortages affecting production and costs.
Inogen, a leader in medical technology specializing in respiratory products, announced management participation in the Stifel Virtual Healthcare Conference on November 17, 2021, at 3:20 p.m. ET. The presentation will be led by President and CEO Nabil Shabshab and CFO Alison Bauerlein. Interested stakeholders can access the webcast through the Inogen Investor Relations page, with a replay available for 90 days post-event. Inogen focuses on developing portable oxygen concentrators to support patients with chronic respiratory conditions.
Limoneira Company (NASDAQ: LMNR) announced the appointment of Elizabeth (Beth) Mora to its Board of Directors, expanding the board to 11 members, nine of whom are independent. Mora brings over 30 years of experience in finance and ESG, having held executive roles at Draper and Harvard. Her expertise is expected to enhance Limoneira's strategic direction and commitment to diversity and sustainability. Mora expressed enthusiasm for contributing to the company's long-term growth while honoring its legacy.
Inogen, Inc (NASDAQ: INGN) will announce its third quarter 2021 financial results on Thursday, November 4, 2021, after market close. The company will host a conference call at 2:00 PM PT / 5:00 PM ET for discussion. Interested parties can join by calling (877) 841-3961 for domestic or (201) 689-8589 for international access. A replay of the call will be available from November 4, 2021, at 4:00 PM PT until November 18, 2021, at 4:00 PM PT. Inogen provides innovative respiratory products for homecare, focusing on portable oxygen concentrators.
Inogen, Inc. (NASDAQ: INGN) has announced the appointment of Dr. Stanislav Glezer as Chief Technology Officer, overseeing R&D, Medical Affairs, and Regulatory Affairs. Dr. Glezer, who joined Inogen in June 2021, brings over 27 years of experience in medical technology. He replaces Brenton Taylor, who will transition out by April 1, 2022. CEO Nabil Shabshab praised Dr. Glezer for his contributions in enhancing product development and market strategies. The management changes are expected to drive innovation and shareholder value, with a focus on improving patient outcomes.
Inogen, Inc. (NASDAQ: INGN) has announced a partnership with Ashfield Healthcare to enhance its sales capabilities by adding around 20 dedicated sales representatives to its prescriber sales organization. The collaboration aims to improve market penetration for portable oxygen concentrators (POCs) and leverage Ashfield's proprietary insights and analytics tools to drive clinician sales performance. CEO Nabil Shabshab emphasized the importance of increasing collaboration with healthcare prescribers to enhance awareness of Inogen’s offerings. This strategy is expected to positively impact patient service in oxygen therapy.
Inogen, Inc. (NASDAQ: INGN) reported a 41.7% increase in second-quarter 2021 revenue, reaching $101.6 million, driven by strong consumer demand and improved pricing. Domestic direct-to-consumer revenue rose 35.6% to $40.9 million, while rental revenue soared 85.2% to $11.3 million. However, the company faces supply chain challenges, particularly due to semiconductor shortages, which are expected to constrain revenue growth and increase costs. As of June 30, 2021, Inogen had $250 million in cash with no debt and anticipates a net loss in the second half of 2021 due to these challenges.
Inogen, Inc (Nasdaq: INGN) will release its second quarter 2021 financial results on August 4, 2021, after market close. A conference call will follow at 1:30pm PT/4:30pm ET to discuss the results. Interested participants can join by calling (877) 841-3961 for domestic or (201) 689-8589 for international access. A replay will be available from August 4, 2021, 3:30pm PT until August 18, 2021. The company focuses on developing and marketing portable oxygen concentrators for chronic respiratory patients.
Inogen has appointed Jason Somer as the new Executive Vice President and General Counsel, effective July 12, 2021. CEO Nabil Shabshab emphasized that Somer's 25 years of legal experience will enhance Inogen's legal and compliance functions, crucial for the company's growth strategy. Somer expressed his commitment to increasing stockholder value while leading the legal organization. His previous roles include serving as head legal counsel at Invoca, and he holds advanced degrees in law and biology.
Inogen, Inc. (NASDAQ: INGN) has appointed Dr. Stanislav Glezer as Executive Vice President and Chief Medical Officer, effective June 21, 2021. CEO Nabil Shabshab expressed confidence that Dr. Glezer's over 25 years of experience in clinical research and medical affairs will enhance Inogen's clinical capabilities and market development efforts. Dr. Glezer aims to lead Medical Affairs, Clinical Research, and Regulatory organizations to improve patient outcomes through clinical evidence collaboration. His previous roles include significant positions at Becton, Dickinson and Company, and Novo Nordisk.
FAQ
What is the current stock price of Inogen (INGN)?
What is the market cap of Inogen (INGN)?
What does Inogen Inc. do?
What is Inogen's flagship product?
How does Inogen sell its products?
Where does Inogen generate most of its revenue?
How many patients use oxygen therapy according to Inogen?
What makes Inogen's products stand out?
What is the mission of Inogen Inc.?
Who inspired the founding of Inogen?
Where can I learn more about Inogen's history?
What is Inogen Inc.'s stock symbol?
